Becton, Dickinson and Company (BD) has partnered with Poland's non-governmental non-profit organisation The Great Orchestra of Christmas Charity (GOCC) to expand testing for bloodstream infections (BSIs) and sepsis management in the country.
The collaboration aims to provide more than 150 healthcare facilities with advanced diagnostic tools from BD, including BD Bruker MALDI Biotyper sirius IVD System and BD Phoenix M50 Systems.
By deploying the microbiology equipment, clinicians will be able to make rapid and accurate patient management decisions.
These advanced systems are integral components of the BD BSI Solution, offering a comprehensive workflow from sample collection to results reporting.
The BD Bruker MALDI Biotyper utilises MALDI-TOF mass spectrometry to identify microorganisms while the BD Phoenix M50 System delivers accurate and timely results for bacterial identification and drug-susceptibility testing.
BD Integrated Diagnostic Solutions, Europe/Middle East/Africa vice-president and general manager Davide Visentin said: “This broad deployment aligns with BD’s commitment to help advance access and health equity and it also supports the mission of GOCC to improve health care in Poland by making medical services more modern and accessible.
“Advanced microbial detection in more locations enables quicker diagnosis of bloodstream infections. We can identify the bug and the drug to help inform appropriate antimicrobial treatment. For patients with sepsis, every hour is critical.”
Sepsis is a potentially fatal condition triggered by BSIs and necessitates swift diagnosis to prevent organ failure, shock, and death.
With an estimated 47 million to 50 million cases and 11 million deaths annually worldwide, the need for rapid detection and appropriate antimicrobial therapy is critical.
BD claims that its technology is designed to facilitate these urgent requirements, offering a faster time for detection and aiding in determining suitable treatment options.
Last month, BD partnered with Camtech Health to enhance access to cervical cancer screening in Singapore by introducing a self-collection human papillomavirus (HPV) test for women to use at home.
